OBM Was Invited by Our Legal Advisor Firm Steinepreis Paganin to Attend IPO Network’s Exclusive Event in Melbourne
30th July 2025
OBM Attends BioAsia-Taiwan Conference and ACRO Biomedical Announces to Outlicense the Market Rights in 10 ASEAN Countries of its Biocompatible Artificial Cornea, ABCcolla Collagen Ophthalmic Matrix, to Vietnam’s CT Group 23th ~ 27 July 2025
July 27, 2025Data Indicate OBM’s OBM1701 Diffuses into the Retina and RPE and Effectively Alleviates Choroidal Neovascularisation in wet-AMD Animal Model after Topically Applied Has Been Published on An Association for Research in Vision and Ophthalmology (ARVO) Official Journal – 19th August 2025
August 19, 2025Oculus Biomed Limited (“OBM”) is invited by its legal advisor, Steinepreis Paganin (“SP”), to attend a function held by the IPO Network, on the evening of 30 July 2025 at 5:30pm at The Douglas Club (472 Bourke St, Melbourne). OBM’s Chairman, Dr Ruchong Ou and CEO Mr Andrew Coloretti together with SP’s partner, Mr. Matt Hawtin, were at the function. IPO Network is a specialty network of professional organisations that assists businesses to, amongst other things, prepare and execute their exit strategy, including but not limited to IPO, and to support listed companies beyond their IPO.
SP is one of the most active corporate law firms, advising Australian public and private companies in the area of capital markets, mergers and acquisitions, corporate compliance, mining and resources, technology, biotechnology and life sciences.
OBM has engaged SP to assist the company for reviewing the current corporate structure and status, advising the legal requirement for capital raising and preparing for IPO. It is OBM’s plan to explore the opportunities to become a public-listed company on the Australian Stock Exchange (ASX) to accelerate the development of OBM’s leading projects to provide eye disease-related patients and society with advanced and favourable ways of treatment.
